<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11944384</article-id><article-id pub-id-type="pmcid-ver">PMC11944384.1</article-id><article-id pub-id-type="pmcaid">11944384</article-id><article-id pub-id-type="pmcaiid">11944384</article-id><article-id pub-id-type="pmid">40142993</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17030330</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00330</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of the Antinociceptive Effect of Sesamin: Role of 5HT<sub>1A</sub> Serotonergic Receptors</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Camacho-Cruz</surname><given-names initials="R">Roberto</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-pharmaceutics-17-00330" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alcal&#225;-Hern&#225;ndez</surname><given-names initials="DF">David Francisco</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af2-pharmaceutics-17-00330" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huerta-Cruz</surname><given-names initials="JC">Juan Carlos</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af3-pharmaceutics-17-00330" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2928-744X</contrib-id><name name-style="western"><surname>Arrieta-Valencia</surname><given-names initials="J">Jes&#250;s</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-pharmaceutics-17-00330" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>S&#225;nchez-Mendoza</surname><given-names initials="ME">Mar&#237;a Elena</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-pharmaceutics-17-00330" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Flores-Murrieta</surname><given-names initials="FJ">Francisco Javier</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af1-pharmaceutics-17-00330" ref-type="aff">1</xref><xref rid="af3-pharmaceutics-17-00330" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2858-8710</contrib-id><name name-style="western"><surname>Navarrete</surname><given-names initials="A">Andr&#233;s</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af4-pharmaceutics-17-00330" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Reyes-Garc&#237;a</surname><given-names initials="JG">Juan Gerardo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af1-pharmaceutics-17-00330" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3199-5683</contrib-id><name name-style="western"><surname>Rocha-Gonz&#225;lez</surname><given-names initials="HI">H&#233;ctor Isaac</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af1-pharmaceutics-17-00330" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-17-00330" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Wang</surname><given-names initials="Z">Zhenjia</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00330"><label>1</label>Escuela Superior de Medicina, Instituto Polit&#233;cnico Nacional, Mexico City 11340, Mexico; <email>rcamchoc1700@alumno.ipn.mx</email> (R.C.-C.); <email>jarrietav@ipn.mx</email> (J.A.-V.); <email>msanchezme@ipn.mx</email> (M.E.S.-M.); <email>fjfloes@ipn.mx</email> (F.J.F.-M.); <email>jgreyes@ipn.mx</email> (J.G.R.-G.)</aff><aff id="af2-pharmaceutics-17-00330"><label>2</label>Divisi&#243;n de Ciencias Biol&#243;gicas y de la Salud, Universidad Aut&#243;noma Metropolitana Unidad Iztapalapa, Mexico City 09340, Mexico</aff><aff id="af3-pharmaceutics-17-00330"><label>3</label>Instituto Nacional de Enfermedades Respiratorias, Ismael Cos&#237;o Villegas, Mexico City 14080, Mexico; <email>juanc.huerta@iner.gob.mx</email></aff><aff id="af4-pharmaceutics-17-00330"><label>4</label>Departamento de Farmacia, Facultad de Qu&#237;mica, Universidad Nacional Aut&#243;noma de M&#233;xico, Mexico City 04510, Mexico; <email>anavarrt@unam.mx</email></aff><author-notes><corresp id="c1-pharmaceutics-17-00330"><label>*</label>Correspondence: <email>hrochag@ipn.mx</email></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2025</year></pub-date><volume>17</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">485337</issue-id><elocation-id>330</elocation-id><history><date date-type="received"><day>21</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>18</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>27</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-28 09:25:15.020"><day>28</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-17-00330.pdf"/><abstract><p><bold>Background/Objectives:</bold> Sesame (<italic toggle="yes">Sesamum indicum</italic> L.) is used in folk medicine to treat painful disorders. Sesamin is the main lignan found in this plant; however, its antinociceptive potential has scarcely been studied. The aim was to investigate the antinociceptive effect of sesamin on inflammatory and neuropathic pain models, as well as the possible mechanism of action through which sesamin mediates its own antinociceptive effect. <bold>Methods:</bold> Formalin and carrageenan animal models were used to assess inflammatory pain, whereas an L5/L6-spinal-nerve-ligated rat model was employed to evaluate neuropathic pain. <bold>Results:</bold> Oral sesamin significantly reduced carrageenan-induced hyperalgesia and inflammation, formalin-induced nociception, and L5/L6-spinal-nerve-ligation-induced allodynia. Sesamin was more effective than diclofenac in the inflammatory pain models, but it was less effective than pregabalin in the neuropathic pain model. The antinociceptive effect of sesamin, in the formalin test, was prevented by the intraperitoneal administration of methiothepin (5-HT<sub>1/5</sub> antagonist), but not by naltrexone (an opioid antagonist) or L-NAME (an NOS inhibitor). In addition, WAY-100635 (5-HT<sub>1A</sub> antagonist), but not SB-224289 (5-HT<sub>1B</sub> antagonist), BRL-15542 (5-HT<sub>1D</sub> antagonist), and SB-699551 (5-HT<sub>5A</sub> antagonist), impeded sesamin-induced antinociception. <bold>Conclusions:</bold> This study&#8217;s results support the use of sesamin to treat inflammatory pain disorders and suggest that 5-HT<sub>1A</sub> receptors influence the antinociceptive effect of this drug.</p></abstract><kwd-group><kwd>diclofenac</kwd><kwd>gabapentin</kwd><kwd>inflammatory pain</kwd><kwd>neuropathic pain</kwd><kwd>serotonergic receptors</kwd><kwd>sesamin</kwd></kwd-group><funding-group><award-group><funding-source>Instituto Politecnico Nacional</funding-source><award-id>20230072</award-id><award-id>20241264</award-id></award-group><funding-statement>This research was partially funded by the Instituto Politecnico Nacional (SIP 20230072 and 20241264).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00330"><title>1. Introduction</title><p>Sesame (<italic toggle="yes">Sesamum indicum</italic> L.) is a warm-season annual plant of the <italic toggle="yes">Pedaliaceae</italic> family. It grows up to 2 m in height and produces bell-shaped pendulous flowers with a soft color ranging from white to pink and purple, and its fruits are rectangular capsules of 2&#8211;3 cm in length and 6&#8211;12 mm in diameter, which open with a pop when the seed matures [<xref rid="B1-pharmaceutics-17-00330" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-17-00330" ref-type="bibr">2</xref>].</p><p>In folk medicine from around the world, sesame seed oil is widely useful to treat wounds, burns, inflammation and several pain disorders, such as dysmenorrhea, abdominal pain, earache, and migraine, among others [<xref rid="B3-pharmaceutics-17-00330" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceutics-17-00330" ref-type="bibr">4</xref>]. Around 160 phytochemical molecules have been isolated from sesame seeds, including lignans, polyphenols, phytosterols, anthraquinones, triterpenes, and other compounds, which have been linked to the health advantages of the seed. Lignans are regarded as the primary active compounds present in sesame seeds, and approximately half of the lignans present in those seeds are sesamin [<xref rid="B4-pharmaceutics-17-00330" ref-type="bibr">4</xref>].</p><p>Several studies have pointed out that sesamin may be an effective therapeutic agent in preventing tumor development and the progression of various types of cancer due to its anti-proliferative, pro-apoptotic, anti-metastatic, and pro-autophagocytic properties [<xref rid="B5-pharmaceutics-17-00330" ref-type="bibr">5</xref>]. In addition, it has been suggested that sesamin may be a good candidate for treating cardiovascular diseases, diabetes, hypertension, atherosclerosis, acute kidney injury, and fatty liver disease since it has antioxidant, anti-inflammatory, anti-hypertensive, hypoglycemic, lipolytic, hypocholesterolemic, anti-atherogenic, and anti-thrombotic activities [<xref rid="B6-pharmaceutics-17-00330" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-17-00330" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-17-00330" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-17-00330" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceutics-17-00330" ref-type="bibr">10</xref>]; however, the potential of sesamin in pain treatment has scarcely been studied.</p><p>The antinociceptive effect of sesamin has been evaluated in ethanolic and ethyl acetate extracts of <italic toggle="yes">Zanthoxylum armatum</italic>. In these studies, the extracts were able to significantly diminish acetic acid-induced visceral pain and formalin-induced inflammatory pain in mice, but the extracts contained a mixture of between 6 and 9 lignans, in which sesamin was not the main lignan [<xref rid="B11-pharmaceutics-17-00330" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceutics-17-00330" ref-type="bibr">12</xref>]. The antinociceptive effect of sesamin has been evaluated in models of phasic pain such as hot-plate and tail immersion, as well as in acetic acid-induced visceral pain, but this effect in inflammatory pain remains controversial because studies have shown conflicting results. Indeed, sesamin was able to reduce the nociceptive behavior induced by formalin in [<xref rid="B13-pharmaceutics-17-00330" ref-type="bibr">13</xref>], but not that of complete Freund adjuvant-induced inflammatory pain in [<xref rid="B14-pharmaceutics-17-00330" ref-type="bibr">14</xref>]. Furthermore, the potential of sesamin as an antinociceptive agent in the treatment of neuropathic pain is unknown, and although the antinociceptive effect of sesamin has been suggested in some pain models, the mechanism of action through which sesamin reduces nociceptive behaviors has not been investigated. To this end, some studies point out that sesamin modulates the serotonin level in the central nervous system to reduce anxiety in several animal models [<xref rid="B15-pharmaceutics-17-00330" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-17-00330" ref-type="bibr">16</xref>]. Serotonin is the major neurotransmitter involved in the descending modulation of spinal nociceptive neurotransmission, and its effect is mainly antinociceptive in the central nervous system, although this depends on the specific serotonin receptor that is activated. The serotonin receptor family consists of 14 members divided into 7 families, where 5-HT<sub>1</sub> and 5-HT<sub>5</sub> receptors are considered inhibitory receptors due to the fact that they are negatively coupled to adenylyl cyclase and hyperpolarize the neurons [<xref rid="B17-pharmaceutics-17-00330" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-17-00330" ref-type="bibr">18</xref>], thus being a potential target through which sesamin induces its antinociceptive effect.</p><p>Consequently, the current study aimed to evaluate the antinociceptive effect of sesamin in formalin- and carrageenan-induced inflammatory pain, as well as its effect in L5/L6-spinal-nerve-ligation-induced neuropathic pain in rats. In addition, the mechanism of action underlaying the antinociceptive effect of sesamin is investigated in the formalin test.</p></sec><sec id="sec2-pharmaceutics-17-00330"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-17-00330"><title>2.1. Animals</title><p>All the behavioral experiments were performed on adult female Wistar rats (180&#8211;220 g). Female rats were used based on the fact that previous experiments in our test conditions have not shown significant differences between both sexes [<xref rid="B19-pharmaceutics-17-00330" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-17-00330" ref-type="bibr">20</xref>]. Animals were obtained from the institutional vivarium at the National Institute of Respiratory Diseases, Ismael Cosio Villegas (INER). Rats were housed in controlled conditions with a 12 h light/dark cycle at room temperature (23&#8211;25 &#176;C) and with free access to food and water. Rats were fasted overnight (12 h) with free access to water before experiments. Experiments were designed to reduce pain and suffering in animals. In addition, the number of animals utilized was the minimum necessary to identify a reliable statistical difference. Animals were randomized into treatment groups a priori using the RandBetween function in Excel. On the experimental day, rats were put in observation acrylic chambers for 30 min to allow them to acclimate to their surroundings and to reduce their stress. Rats were euthanized in a carbon dioxide chamber at the end of the experimental paradigm. Only the observer was unaware of the treatment given to each animal during the evaluation.</p></sec><sec id="sec2dot2-pharmaceutics-17-00330"><title>2.2. Drugs</title><p>Formaldehyde and carrageenan were purchased from Sigma Aldrich (St. Louis, MO, USA). Methiothepin (1-[10,11-dihydro-8-(methylthio)dibenzo[b,f]thiepin-10-yl]-4-methylpiperazine mesylate salt), L-NAME (N&#969;-nitro-L-arginine methyl ester hydrochloride), naltrexone ((5&#945;)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydromorphinan-6-one hydrochloride), WAY100635 (N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2 pyridinylcyclohexanecarboxamide maleatesalt), SB224289 (1&#8242;-methyl-5-[[2&#8242;-methyl-4&#8242;(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7- etrahydrospiro[furo[2,3-f]indole-3,4&#8242;-piperidine]hydrochloride), BRL15572 (4-(3-chlorophenyl)-&#945;-(diphenylmethyl)-1-piperazineethanol hydrochloride), and SB699551 (N-[2- dimethylamino)ethyl]-N-[[4&#8242;-[[(2-phenylethyl)amino]methyl][1,1&#8242;-biphenyl]-4yl]-methyl] and clopentanepropanamide dihydrochloride) were acquired from Tocris Biosciences (Bristol, Avon, UK). Methiothepin (non-selective 5-HT antagonist) [<xref rid="B21-pharmaceutics-17-00330" ref-type="bibr">21</xref>], L-NAME (non-selective nitric oxide synthase inhibitor) [<xref rid="B22-pharmaceutics-17-00330" ref-type="bibr">22</xref>], naltrexone (non-selective opioid antagonist) [<xref rid="B23-pharmaceutics-17-00330" ref-type="bibr">23</xref>], WAY100635 (5-HT<sub>1A</sub> antagonist) [<xref rid="B24-pharmaceutics-17-00330" ref-type="bibr">24</xref>], SB224289 (5-HT<sub>1B</sub> antagonist) [<xref rid="B25-pharmaceutics-17-00330" ref-type="bibr">25</xref>], BRL15572 (5-HT<sub>1D</sub> antagonist) [<xref rid="B26-pharmaceutics-17-00330" ref-type="bibr">26</xref>], and SB699551 (5-HT<sub>5A</sub> antagonist) [<xref rid="B27-pharmaceutics-17-00330" ref-type="bibr">27</xref>] were chosen based on their selectivity according to the literature. Formaldehyde and carrageenan were prepared in a 0.9% physiological saline solution. Due to sesamin and some antagonists being water-insoluble compounds, we decided to use a mixture of physiological saline solution/dimethyl sulfoxide (90:10 v/v) as the vehicle (control group) to suspend them. The oral administration of this vehicle did not significantly modify the nociceptive responses with respect to the oral administration of a physiological saline solution vehicle. All drugs were freshly prepared before experiments. Doses of sesamin, antagonists, and the inhibitor were selected on the basis of previous studies and pilot experiments in our laboratory [<xref rid="B13-pharmaceutics-17-00330" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-17-00330" ref-type="bibr">14</xref>,<xref rid="B28-pharmaceutics-17-00330" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-00330" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00330" ref-type="bibr">30</xref>].</p></sec><sec id="sec2dot3-pharmaceutics-17-00330"><title>2.3. Plant Material</title><p>Sesame seeds (<italic toggle="yes">Sesamum indicum</italic>) were purchased from the Central de Abasto in M&#233;xico City, Mexico. Sesamin was extracted according to the previously described procedure with some modifications [<xref rid="B31-pharmaceutics-17-00330" ref-type="bibr">31</xref>]. In brief, the seeds (4 kg) were subjected to grinding and extraction under reflux with n-hexane (3L) for 3 h three times. The evaporation of the solvent in vacuum yielded 250 g of oil sesame. Then, the oil sesame was fractionated using silica gel column chromatography. Elution was started with 100% hexane, and the polarity was increased using hexane/ethyl acetate mixtures in proportions of 9:1 and 8:2 in a gradient elution technique. A total of 60 fractions of 50 mL each were collected and screened via thin-layer chromatography using a reference sample of sesamin (Sigma Aldrich, St. Louis, MO, USA). The fractions containing sesamin (fractions 40&#8211;60, 8:2 hexane/ethyl acetate) were pooled and subjected to a second column of silica gel eluted with the same gradient elution technique mentioned above. From the second column, a total of 50 fractions of 50 mL each were obtained, where fractions 30 to 37 (8:2 hexane/ethyl acetate) yielded a white solid, which was purified via re-crystallization with hot ethanol until the fractions were akin to colorless needles (2.5 g, 0.063%). The crystals had a melting point of 122&#8211;123 &#176;C, which corresponded to sesamin. To confirm the structure and molecular weight (354.11 g/mol) of sesamin, an electrospray ionization (ESI) analysis was performed using a Bruker micrOTOF-Q II mass spectrometer (Bruker Daltonics, Billerica, MA, USA). Using this technique, the sample was dissolved in ethanol and directly injected into the spectrometer under the following conditions: a capillary potential of &#8722;4.5 kV, a dry gas temperature at 200 &#176;C, a dry gas flow of 4 L/min, and a mass range of 500 to 3000 <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>. The mass spectrometry data were processed using PolyTools 1.0 (Bruker Daltonics, Billerica, MA) [<xref rid="B32-pharmaceutics-17-00330" ref-type="bibr">32</xref>].</p></sec><sec id="sec2dot4-pharmaceutics-17-00330"><title>2.4. Formalin Test</title><p>To confirm the antinociceptive effect of sesamin in inflammatory pain and to evaluate its mechanism of action, we performed the formalin test [<xref rid="B33-pharmaceutics-17-00330" ref-type="bibr">33</xref>]. For this purpose, the rats were placed in 20 cm diameter and 30 cm high acrylic observation chambers with mirrors behind for 30 min to allow them to adapt to their environment. After this period, rats received a subcutaneous injection of 1% formalin (50 &#956;L) in the region dorsal of the right hind paw using a 30 g needle. The nociceptive behavior was quantified as the number of flinches of the injected paw at intervals of 1 min every 5 min for 60 min [<xref rid="B34-pharmaceutics-17-00330" ref-type="bibr">34</xref>]. The formalin-induced paw pain score was divided into phase 1 (0&#8211;10 min) and phase 2 (10&#8211;60 min). In this nociceptive model, 12 h fasted rats received an oral dose of vehicle (1 mL/kg), sesamin (0.32, 1, 3.2, and 10 mg/kg), or diclofenac (1, 3.2, 10, and 32 mg/kg) 60 min prior to formalin injection. To discern the mechanism of action of sesamin, rats received two doses in total, namely an oral dose of 3 mg/kg sesamin 60 min before 1% formalin injection and an intraperitoneal dose of naltrexone (1 mg/kg), L-NAME (0.1 mg/kg), methiothepin (1 mg/kg), WAY100635 (30 &#956;g/kg), SB224289 (0.3 &#956;g/kg), BRL15572 (30 &#956;g/kg), or SB699551 (30 &#956;g/kg) 30 min before formalin injection.</p></sec><sec id="sec2dot5-pharmaceutics-17-00330"><title>2.5. Thermal Hyperalgesia</title><p>To evaluate the antihyperalgesic effect of sesamin, 12 h fasted rats received a single oral dose of vehicle (1 mL/kg body weight) or increasing doses of sesamin (3.2, 5.6, 10, and 32 mg/kg) or diclofenac (3.2, 5.6, 10, and 32 mg/kg) just prior to the plantar 1% carrageenan injection. Thermal hyperalgesia was measured via the thermal nociception test device (Torrey Pines Instruments, San Diego, CA, USA), as previously described [<xref rid="B35-pharmaceutics-17-00330" ref-type="bibr">35</xref>]. In this model, the rats were placed individually into acrylic boxes on the glass surface of the device. Once the rats were acclimated for 30 min, a thermal nociceptive stimulus was manually placed under the right hind paw before and every half hour until 6 h after carrageenan injection (50 &#956;L, i.pl.). In each measurement, a timer was automatically started when the thermal stimulus was placed under the paw, and it stopped when the rat removed the paw. Thus, the nociceptive time latency was defined as the time required for paw withdrawal. A time cut-off of 20 s was fixed to elude tissue damage.</p></sec><sec id="sec2dot6-pharmaceutics-17-00330"><title>2.6. Carrageenan-Induced Paw Edema</title><p>The anti-inflammatory effect of sesamin was evaluated with the aid of a plethysmometer (Plethysmometer 7150; Ugo Basile, Gemonio, Italy) according to the method previously described by Winder et al. [<xref rid="B36-pharmaceutics-17-00330" ref-type="bibr">36</xref>]. The device consisted of two interconnected methacrylate tubes filled with 0.9% physiological saline solution: in the longer one (18 mm in diameter), the injected paw of the rat was introduced in each measurement, whereas the shorter one had a transducer that measured the volume displaced in the long tube. On the day of evaluation, 12 h fasted rats were orally administered with vehicle (1 mL/kg) or increasing doses of sesamin (3.2, 5.6, 10, and 32 mg/kg) or diclofenac (3.2, 5.6, 10, and 32 mg/kg). Immediately afterwards, the rats received an intraplantar injection of 1% carrageenan (50 &#956;L) in the right hind paw to induce the edema. Paw volume was measured before and after 1, 2, 3, 4, 5, and 6 h of carrageenan injection. To determine the differences in paw volume in &#956;L (&#916;Volume) with respect to the basal, the paw was submerged up to the tibiotarsal joint every time.</p></sec><sec id="sec2dot7-pharmaceutics-17-00330"><title>2.7. L5/L6-Spinal-Nerve-Ligation-Induced Tactile Allodynia</title><p>To test the antinociceptive effect of sesamin in a neuropathic pain model, we used the tactile allodynia model described by Chaplan et al., 1994 [<xref rid="B37-pharmaceutics-17-00330" ref-type="bibr">37</xref>]. To perform this procedure, rats received an intraperitoneal injection of a mixture of ketamine/xylazine (45 and 12 mg/kg, respectively) to induce anesthesia. Then, rats were placed under a stereoscopic microscope, and the vertebral column was exposed in its lumbar area localizing the right L5 and L6 spinal nerves, which were ligated with a 6-0 silk suture distal to the dorsal root ganglion. Sham-operated rats were subjected to the same procedure; however, nerves were not ligated. Immediately, incision was sutured, and the rats were housed until recovery (14 days). Animals with motor deficiency were not included in the behavioral evaluation.</p><p>On the evaluation day, 12 h fasted rats were put into a transparent acrylic box on a metal mesh platform for 30 min to allow them to acclimate to their surroundings. Later on, rats were orally administered with vehicle (1 mL/kg), sesamin (3.2, 10, 32, and 100 mg/kg), or pregabalin (0.03, 1, 10, and 32 mg/kg). Tactile allodynia was evaluated by measuring the 50% paw withdrawal threshold in response to a set of calibrated von Frey filaments (Stoleting Co., Wood Dale, IL, USA) between 0.41 g (3.9 mN) and 15.1 g (147.1 mN), according to the previously described up&#8211;down threshold technique [<xref rid="B37-pharmaceutics-17-00330" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-17-00330" ref-type="bibr">38</xref>]. In this technique, an initial filament of 2 g was presented in the middle part of the right hind paw plantar surface, avoiding the paw pad, for 5 s. The positive response, observed as an abrupt withdrawal of the paw, was then followed by the application of a thinner filament, or a thicker filament, if the paw was not removed from the mechanical stimulus. After a response change was found, the rat was evaluated four more times to identify a pattern of six responses. The 50% paw withdrawal threshold was measured at 0, 0.5, 1, 2, 3, 4, 5, and 6 h and was calculated using the following formula:<disp-formula id="FD1-pharmaceutics-17-00330"><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mn>50</mml:mn><mml:mo>%</mml:mo><mml:mo>&#160;</mml:mo><mml:mi>paw</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>withdrawal</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>threshold</mml:mi><mml:mo>&#160;</mml:mo><mml:mo>(</mml:mo><mml:mi mathvariant="normal">g</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo></mml:mrow><mml:mo>&#160;</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mfenced><mml:mrow><mml:mi>X</mml:mi><mml:mi>f</mml:mi><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:mi>&#948;</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mrow><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mn>000</mml:mn></mml:mrow></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula>
where <italic toggle="yes">Xf</italic> is the last value of the von Frey filament used in log units, <italic toggle="yes">k</italic> is the tabular value for the pattern of the six responses [<xref rid="B37-pharmaceutics-17-00330" ref-type="bibr">37</xref>], and <italic toggle="yes">&#948;</italic> is the mean difference between stimuli. All the rats included in this study responded to a basal stimulus of less than 4 g.</p></sec><sec id="sec2dot8-pharmaceutics-17-00330"><title>2.8. Statistical Analysis</title><p>In all the behavioral studies, data were recorded as the mean &#177; S.E.M. of 6&#8211;8 rats per experimental group. For the formalin test, the time courses of the number of flinches were used to calculate the AUC of phase 1 and phase 2 of the test. From the AUC, the % antinociception for each phase was calculated using the following equation.<disp-formula id="FD2-pharmaceutics-17-00330"><mml:math id="mm2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mo>%</mml:mo><mml:mi>Antinociception</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mo>&#160;</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>AUC</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi>Vehicle</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>flinches</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mrow><mml:mi>AUC</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi>Test</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>flinches</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>AUC</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi>Vehicle</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>flinches</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&#160;</mml:mo><mml:mo>&#215;</mml:mo><mml:mo>&#160;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>In the carrageenan-induced hyperalgesia and inflammation experiments, time courses of paw withdrawal latency time (s) or volume change (&#916;V in &#181;L) were generated, respectively. From time courses, the area under the curve (AUC) was obtained via the trapezoidal rule. Then, the % anti-inflammatory effect was calculated via the following formula.<disp-formula id="FD3-pharmaceutics-17-00330"><mml:math id="mm3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mo>%</mml:mo><mml:mi>Anti</mml:mi><mml:mo>-</mml:mo><mml:mi>inflammatory</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>effect</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mo>&#160;</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>AUC</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi>Vehicle</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>volume</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mrow><mml:mi>AUC</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi>Test</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>volume</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>AUC</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi>Vehicle</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>volume</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&#160;</mml:mo><mml:mo>&#215;</mml:mo><mml:mo>&#160;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>In contrast, the percentage of maximum possible effect (%MPE) for antihyperalgesic effect was determined via the next equation.<disp-formula id="FD4-pharmaceutics-17-00330"><mml:math id="mm4" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mo>%</mml:mo><mml:mi>MPE</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mo>&#160;</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>AUC</mml:mi></mml:mrow><mml:mrow><mml:mi>Test</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>latency</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mrow><mml:mi>AUC</mml:mi></mml:mrow><mml:mrow><mml:mi>Vehicle</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>latency</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>AUC</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi>Cut</mml:mi><mml:mo>-</mml:mo><mml:mi>off</mml:mi></mml:mrow><mml:mo>&#160;</mml:mo><mml:mrow><mml:mn>20</mml:mn><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mo>&#160;</mml:mo><mml:mi>latency</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mrow><mml:mi>AUC</mml:mi></mml:mrow><mml:mrow><mml:mi>Vehicle</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>latency</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&#160;</mml:mo><mml:mo>&#215;</mml:mo><mml:mo>&#160;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>For the tactile allodynia model, the AUC was obtained via the trapezoidal rule from the time courses of the 50% paw withdrawal threshold. After that, the %MPE was calculated via the following formula.<disp-formula id="FD5-pharmaceutics-17-00330"><mml:math id="mm5" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mo>%</mml:mo><mml:mi>MPE</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mo>&#160;</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>AUC</mml:mi></mml:mrow><mml:mrow><mml:mi>Test</mml:mi><mml:mo>&#160;</mml:mo><mml:mrow><mml:mi>tactile</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>threshold</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mrow><mml:mi>AUC</mml:mi></mml:mrow><mml:mrow><mml:mi>Vehicle</mml:mi><mml:mo>&#160;</mml:mo><mml:mrow><mml:mi>tactile</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>threshold</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>AUC</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi>Sham</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>tactile</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>threshold</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mrow><mml:mi>AUC</mml:mi></mml:mrow><mml:mrow><mml:mi>Vehicle</mml:mi><mml:mo>&#160;</mml:mo><mml:mrow><mml:mi>tactile</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>threshold</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&#160;</mml:mo><mml:mo>&#215;</mml:mo><mml:mo>&#160;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Later on, dose&#8211;response curves were constructed for each experimental model. The data distribution was evaluated using the Kolmogorov&#8211;Smirnov test, whereas the equality of variances between groups was evaluated using the Brown&#8211;Forsythe test and Bartlett&#8217;s test. Statistical differences between groups were determined via one-way analysis of variance (ANOVA), followed by Tukey&#8217;s test. For all cases, the statistical difference was considered significant when the <italic toggle="yes">p</italic> value was less than 0.05. Effective dose 30 (ED<sub>30</sub>) or effective dose 50 (ED<sub>50</sub>) &#177; error standard of the mean was calculated for each dose&#8211;response curve via Hill&#8217;s equation. Graphs were constructed using GraphPad Prism 9.5.</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-17-00330"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-17-00330"><title>3.1. Sesamin Reduces Formalin-Induced Nociception in Rats</title><p>The subcutaneous injection of 1% formalin into the dorsal surface of the right hind paw of a rat induced a spontaneous flinching behavior characterized by a typical biphasic time course. Phase 1 of the nociceptive behavior took place within 0&#8211;10 min after formalin injection, whereas phase 2 occurred with a duration of about 50 min (10&#8211;60 min), with a maximum value achieved at around 20 min. In this inflammatory pain model, the oral administration of both 3.2 mg/kg sesamin and 32 mg/kg diclofenac reduced formalin-induced flinching behavior with respect to the vehicle group along the time course (<xref rid="pharmaceutics-17-00330-f001" ref-type="fig">Figure 1</xref>A). In the dose&#8211;response curves, it is shown that sesamin significantly and dose-dependently reduced formalin-induced nociception between 0.32 and 3.2 mg/kg along phase 2, but only showed a decreasing trend during phase 1. Furthermore, sesamin attained its maximum effect at 3.2 mg/kg (61.8 &#177; 5.6%), and higher doses of sesamin did not produce a greater antinociceptive effect, showing an ED<sub>30</sub> = 0.9 &#177; 1.8 mg/kg during phase 2. In a similar way, oral diclofenac significantly diminished the number of flinches induced by formalin in phase 2, but not in phase 1. Diclofenac presented an efficacy of 46.8 &#177; 7.0% at 32 mg/kg and an ED<sub>30</sub> = 1.8 &#177; 2.8 mg/kg during phase 2. In the formalin test, sesamin was equieffective (<italic toggle="yes">p</italic> &gt; 0.05) and equipotent (<italic toggle="yes">p</italic> &gt; 0.5) to diclofenac (<xref rid="pharmaceutics-17-00330-f001" ref-type="fig">Figure 1</xref>B,C).</p></sec><sec id="sec3dot2-pharmaceutics-17-00330"><title>3.2. Oral Administration of Sesamin Reduces Carrageenan-Induced Hyperalgesia in Rats</title><p>The intraplantar injection of 1% carrageenan into the right hind paw gradually diminished the paw withdrawal latency time in the vehicle group (<xref rid="pharmaceutics-17-00330-f002" ref-type="fig">Figure 2</xref>A). On the contrary, the oral administration of sesamin (3.2&#8211;32 mg/kg) or diclofenac (3.2&#8211;32 mg/kg) dose-dependently prevented carrageenan-induced hyperalgesia (<xref rid="pharmaceutics-17-00330-f002" ref-type="fig">Figure 2</xref>B). In the time courses, 32 mg/kg of sesamin evoked its maximum effect at 0.5 h; this effect was maintained for about 2.5 h and then began to decline until reaching a basal value after 6 h. For its part, 32 mg/kg of diclofenac kept baseline latency times throughout the time course (<xref rid="pharmaceutics-17-00330-f002" ref-type="fig">Figure 2</xref>A). In this model, sesamin was more effective (<italic toggle="yes">p</italic> &#706; 0.001) than diclofenac at the tested doses because sesamin reached an efficacy of 80.2 &#177; 1.2%, whereas diclofenac achieved an efficacy of 52.9 &#177; 1.0 at the highest dose tested. Similarly, sesamin showed a lower potency (ED<sub>50</sub> = 6.7 &#177; 1.9 mg/kg) than diclofenac (ED<sub>50</sub> = 10.4 &#177; 1.5), but without statistical significance (<italic toggle="yes">p</italic> &lt; 0.16). Both drugs were significantly different to the vehicle in the dose range of 3.2 to 32 mg/kg (<xref rid="pharmaceutics-17-00330-f002" ref-type="fig">Figure 2</xref>B).</p></sec><sec id="sec3dot3-pharmaceutics-17-00330"><title>3.3. Sesamin Orally Decreases Carrageenan-Induced Inflammation in Rats</title><p>In the vehicle group, the intraplantar administration of 1% carrageenan into the right hind paw increased the paw volume (<xref rid="pharmaceutics-17-00330-f002" ref-type="fig">Figure 2</xref>C). On the other hand, the oral administration of sesamin (3.2&#8211;32 mg/kg) or diclofenac (3.2&#8211;32 mg/kg) reduced carrageenan-induced inflammation in a dose-dependent manner (<xref rid="pharmaceutics-17-00330-f002" ref-type="fig">Figure 2</xref>D). In the time courses of volume that can be observed in the vehicle group, paw inflammation was progressively increased for at least 6 h. Meanwhile, oral sesamin (32 mg/kg) or diclofenac (32 mg/kg) reduced the gradual increase in paw volume induced by 1% carrageenan along the time course (<xref rid="pharmaceutics-17-00330-f002" ref-type="fig">Figure 2</xref>C). In the dose&#8211;response curves, it can be noticed that both sesamin and diclofenac achieved a significant anti-inflammatory effect from 5.6 mg/kg onwards. Sesamin was more potent (<italic toggle="yes">p</italic> &lt; 0.02) and effective (<italic toggle="yes">p</italic> &#706; 0.001) than diclofenac in carrageenan-induced inflammation, since sesamin reached an efficacy of 64.3 &#177; 0.9% and had an ED<sub>30</sub> = 5.5 &#177; 1.9 mg/kg, whereas diclofenac attained an efficacy of 35.6 &#177; 3.5% and an ED<sub>30</sub> = 15.5 &#177; 3.3 mg/kg (<xref rid="pharmaceutics-17-00330-f002" ref-type="fig">Figure 2</xref>D).</p></sec><sec id="sec3dot4-pharmaceutics-17-00330"><title>3.4. Oral Administration of Sesamin Induces a Moderate Antiallodynic Effect in Rats Subjected to Spinal Nerve L5/L6 Ligation</title><p>Rats subjected to spinal nerve L5/L6 ligation showed reductions in the 50% withdrawal threshold to values less than 4 g, which was interpreted as tactile allodynia. In contrast, sham-operated rats maintained their 50% withdrawal threshold at values around 12 g. Allodynia was present in the rats from the first day following spinal surgery and persisted for at least 14 days, when the drugs were administered. The oral administration of 100 mg/kg sesamin slightly increased the 50% withdrawal threshold with a maximal antiallodynic effect at about 4h; then, the effect progressively decreased to basal values after 6 h. For its part, the oral administration of 30 mg/kg pregabalin gradually increased the 50% withdrawal threshold until achieving its maximum effect at around 2 h; then, the effect lasted for at least 6 h (<xref rid="pharmaceutics-17-00330-f003" ref-type="fig">Figure 3</xref>A). The oral administration of increasing doses of sesamin (3&#8211;100 mg/kg) resulted in a moderate dose&#8211;dependent antiallodynic effect. Conversely, oral pregabalin (0.3&#8211;30 mg/kg) dose-dependently increased its antiallodynic effect until reaching values close to 100% effect. In this model of neuropathic pain, pregabalin was clearly more effective (<italic toggle="yes">p</italic> &#706; 0.001) and potent (<italic toggle="yes">p</italic> &#706; 0.001) than sesamin, because pregabalin had an efficacy of 107 &#177; 1.6% and an ED<sub>30</sub> = 9.8 &#177; 1.9 mg/kg, whereas sesamin presented an efficacy of 34.3 &#177; 2.0% and an ED<sub>30</sub> = 56.5 &#177; 2.2 mg/kg. Both drugs were significantly different to the vehicle group in the tested dose range (<xref rid="pharmaceutics-17-00330-f003" ref-type="fig">Figure 3</xref>B).</p></sec><sec id="sec3dot5-pharmaceutics-17-00330"><title>3.5. Sesamin Reduced Formalin-Induced Flinching Behavior Through the Activation of 5-HT1A Receptors</title><p>The mechanism of action of sesamin was elucidated using the 1% formalin test. In this test, the intraperitoneal injection of 1 mg/kg naltrexone (non-selective antagonist opioid receptors; <xref rid="pharmaceutics-17-00330-f004" ref-type="fig">Figure 4</xref>A,B) or 0.1 mg/kg L-NAME (non-selective nitric oxide synthase inhibitor, <xref rid="pharmaceutics-17-00330-f004" ref-type="fig">Figure 4</xref>C,D) did not reduce the antinociceptive effect induced by the previous oral administration of sesamin (3.2 mg/kg) in phase 2. In marked contrast, the intraperitoneal injection of 1 mg/kg methiothepin (non-selective antagonist of 5-HT<sub>1/5</sub> receptors, <xref rid="pharmaceutics-17-00330-f004" ref-type="fig">Figure 4</xref>E,F) blocked the antinociceptive effect exerted by sesamin in phase 2 of the formalin test. In this set of experiments, the doses of naltrexone (1 mg/kg), L-NAME (0.1 mg/kg), or methiothepin (1 mg/kg) did not modify the number of flinches induced by 1% formalin per se (<xref rid="pharmaceutics-17-00330-f004" ref-type="fig">Figure 4</xref>B,D,F).</p><p>More selective antagonists of serotonin receptors were evaluated with sesamin because methiothepin reversed the antinociceptive effect of sesamin. In this way, only the intraperitoneal injection of 30 &#956;g/kg WAY-100635 (5-HT<sub>1A</sub> antagonist; <xref rid="pharmaceutics-17-00330-f005" ref-type="fig">Figure 5</xref>A,B) prevented sesamin-induced antinociception in phase 2 of the formalin test.</p><p>Unlike the intraperitoneal injection of 3 &#956;g/kg SB224289 (5-HT<sub>1B</sub> antagonist; <xref rid="pharmaceutics-17-00330-f005" ref-type="fig">Figure 5</xref>C,D), 30 &#956;g/kg BRL15572 (5-HT<sub>1D</sub> antagonist; <xref rid="pharmaceutics-17-00330-f005" ref-type="fig">Figure 5</xref>E,F) and 30 &#956;g/kg SB699551 (5-HT<sub>5A</sub> antagonist; <xref rid="pharmaceutics-17-00330-f005" ref-type="fig">Figure 5</xref>G,H) did not alter the decrease in the number of flinches induced by a previous oral administration of sesamin (<xref rid="pharmaceutics-17-00330-f005" ref-type="fig">Figure 5</xref>). The doses of WAY-100635 (30 &#956;g/kg), SB-224289 (3 &#956;g/kg), BRL-15572 (30 &#956;g/kg), and SB-699551 (30 &#956;g/kg) did not affect the nociceptive behavior induced by formalin in the rats per se, and such doses were selected on the basis of previous studies [<xref rid="B28-pharmaceutics-17-00330" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-00330" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00330" ref-type="bibr">30</xref>].</p></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-17-00330"><title>4. Discussion</title><p>This study aimed to characterize the antinociceptive potential of sesamin in various pain models in rats and to explore its mechanism of action. According to our results, increasing oral doses of sesamin showed a dose-dependent antinociceptive effect in the formalin-induced inflammatory pain model in rats. In line with our results, previous studies have demonstrated that some extracts from <italic toggle="yes">Zanthoxylum</italic> sp., containing sesamin, among other lignans, were able to reduce the time the mice spent licking the paw injected with formalin [<xref rid="B11-pharmaceutics-17-00330" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceutics-17-00330" ref-type="bibr">12</xref>]. Furthermore, Monteiro et al. [<xref rid="B13-pharmaceutics-17-00330" ref-type="bibr">13</xref>] pointed out that doses of sesame oil and sesamin between 100 and 200 mg/kg have the capacity to significantly reduce the paw-licking time induced by formalin in mice. In contrast with the doses used in mice, we observed that sesamin significantly reduced the formalin-induced number of flinches during phase 2 at doses between 10 and 100 times lower in rats. Such differences can be attributed to the species used, as it is well established that hepatic drug metabolism in mice is faster than that in rats [<xref rid="B39-pharmaceutics-17-00330" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-17-00330" ref-type="bibr">40</xref>]. Our results confirm the antinociceptive effect of sesamin in the formalin test and extend that effect to rats.</p><p>The antinociceptive effect of sesamin alone or contained in extracts has been suggested in models of phasic pain such as hot-plate or tail immersion, as well as in visceral pain models such as the acetic acid-induced writhing test, but it has only been demonstrated in the formalin test as an inflammatory pain model [<xref rid="B11-pharmaceutics-17-00330" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceutics-17-00330" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-17-00330" ref-type="bibr">13</xref>]. In fact, the chronic administration of sesamin did not decrease mechanical allodynia or thermal hyperalgesia in inflammatory pain induced by the hind paw injection of complete Freund adjuvant in mice [<xref rid="B14-pharmaceutics-17-00330" ref-type="bibr">14</xref>]. In this regard, we decided to confirm the antinociceptive effect of sesamin in the carrageenan-induced inflammatory pain model in rats. Thus, the oral administration of increasing doses of sesamin dose-dependently reversed thermal hyperalgesia elicited by carrageenan. Taking these data together, we can confirm that sesamin is effective at reducing inflammatory pain induced by different stimuli. Regarding this point, we hypothesize that the lack of antinociceptive effect observed with complete Freund adjuvant, a model commonly used to mimic the nociceptive and inflammatory conditions of rheumatoid arthritis in an animal, is due to the dose used (80 mg/kg) in that study [<xref rid="B14-pharmaceutics-17-00330" ref-type="bibr">14</xref>], rather than the model itself or ineffectiveness of sesamin, since it has been demonstrated that sesamin achieves a statistically significant antinociceptive effect at doses &#8805; 100 mg/kg in mice [<xref rid="B13-pharmaceutics-17-00330" ref-type="bibr">13</xref>]. In addition, a clinical study performed in 44 patients with rheumatoid arthritis demonstrated that 200 mg/day of sesamin supplementation for 6 weeks can diminish the number of tender joints and the severity of pain [<xref rid="B41-pharmaceutics-17-00330" ref-type="bibr">41</xref>].</p><p>In our study, both in the formalin test and in the carrageenan model, sesamin was equipotent and more effective than diclofenac, the nonsteroidal anti-inflammatory drug (NSAID) most commonly prescribed worldwide to treat and manage pain associated with inflammatory conditions [<xref rid="B42-pharmaceutics-17-00330" ref-type="bibr">42</xref>]. These results allow us to suggest that sesamin may be a therapeutic alternative for the treatment of inflammatory pain because it may have an advantage over diclofenac and other NSAIDs due to the scientific evidence that supports its beneficial effect on systems [<xref rid="B7-pharmaceutics-17-00330" ref-type="bibr">7</xref>,<xref rid="B9-pharmaceutics-17-00330" ref-type="bibr">9</xref>,<xref rid="B43-pharmaceutics-17-00330" ref-type="bibr">43</xref>] that are traditionally affected by NSAIDs, such as cardiovascular, renal, hepatic, and gastrointestinal systems [<xref rid="B44-pharmaceutics-17-00330" ref-type="bibr">44</xref>]. It is fair to say that the main limitation of this study is that it is a single-dose study; however, sesamin has been found in a repeat-dose study to treat rheumatoid arthritis in humans. In that study, 200 mg/day of sesamin for up to 6 weeks reduced the number of tender joints without any severe adverse events [<xref rid="B41-pharmaceutics-17-00330" ref-type="bibr">41</xref>]. Thus, the evidence suggests that sesamin may be used as an adjuvant treatment to counterbalance the adverse effects of NSAIDs, which would allow the administration of these drugs for longer periods without sacrificing their analgesic efficacy.</p><p>Our results also indicate that the oral administration of sesamin produced an anti-inflammatory effect in the rats subjected to carrageenan injection. Concordantly, Monteiro et al. [<xref rid="B13-pharmaceutics-17-00330" ref-type="bibr">13</xref>] previously reported similar results in this model. Although the mechanism of anti-inflammatory action of sesamin has not been evaluated directly in the paw injected with carrageenan, the evidence suggests that sesamin inhibits the infiltration of leucocytes and decreases the exudate volume in a carrageenan-induced lung inflammation model [<xref rid="B13-pharmaceutics-17-00330" ref-type="bibr">13</xref>,<xref rid="B45-pharmaceutics-17-00330" ref-type="bibr">45</xref>]; such effects seem to be associated with reductions in the expression of interleukin (IL)-1&#946;, IL-8, tumor necrosis factor (TNF)-&#945;, and macrophage-inflammatory protein 2 [<xref rid="B45-pharmaceutics-17-00330" ref-type="bibr">45</xref>]. In another study, the daily oral administration of sesamin for 6 weeks improved the number of tender joints in patients with rheumatoid arthritis through reductions in serum levels of C reactive protein, TNF-&#945;, and cyclooxygenase-2 [<xref rid="B41-pharmaceutics-17-00330" ref-type="bibr">41</xref>].</p><p>On the other hand, to establish the antinociceptive potential of sesamin in a neuropathic pain model, we decided to measure the antiallodynic effect of sesamin in spinal-nerve-ligated (L5/L6) rats. In this model, sesamin produced a moderate reduction in allodynia, which was lower in potency and efficacy than that with pregabalin, a voltage-gated calcium channel blocker used to treat pain linked to spinal cord injury and other neuropathic pain disorders [<xref rid="B46-pharmaceutics-17-00330" ref-type="bibr">46</xref>]. To the best of our knowledge, this is the first report which shows the antineuropathic effect of sesamin; although this effect was moderate, we think that the potential of sesamin should be evaluated in other neuropathic pain conditions that take advantage of its pharmacological properties. In this respect, painful diabetic neuropathy is caused by chronic high blood glucose, which leads to accumulating reactive oxygen species, inflammation, and cellular damage [<xref rid="B47-pharmaceutics-17-00330" ref-type="bibr">47</xref>]. As a result, sesamin may offer a more comprehensive treatment of diabetic neuropathy because it has antioxidant [<xref rid="B7-pharmaceutics-17-00330" ref-type="bibr">7</xref>], anti-inflammatory [<xref rid="B10-pharmaceutics-17-00330" ref-type="bibr">10</xref>], hypoglycemic [<xref rid="B6-pharmaceutics-17-00330" ref-type="bibr">6</xref>], and antineuropathic properties (this study).</p><p>To date, there have been no previous reports that analyze the mechanism of the antinociceptive effect of sesamin. Thus, the mechanism of action of sesamin was assessed in the formalin test because it was more effective in inflammatory pain than neuropathic pain. In a first set of experiments, we decided to administer L-NAME (nitric oxide synthase inhibitor), naltrexone (non-selective opioid receptor antagonist), and methiothepin (non-selective serotonin receptor antagonist) to evaluate nitrergic, opioidergic, and serotonergic systems, respectively, since they are common targets for natural products [<xref rid="B27-pharmaceutics-17-00330" ref-type="bibr">27</xref>,<xref rid="B48-pharmaceutics-17-00330" ref-type="bibr">48</xref>]. In the current study, the intraperitoneal injection of methiothepin was able to reverse the antinociception induced by sesamin in phase 2 of the formalin test. On the contrary, naltrexone or L-NAME did not do so. These results suggested that the serotonergic pathway, but not the opioidergic or nitrergic ones, is implicated in the antinociceptive effect of sesamin. In addition, our data are in line with anxiety studies, where it is shown that sesamin is capable of modulating the serotonin level in the brain [<xref rid="B15-pharmaceutics-17-00330" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-17-00330" ref-type="bibr">16</xref>].</p><p>To investigate the type of serotonin receptors involved in the antinociceptive effect of sesamin, we selected 5-HT<sub>1A/B/D</sub> and 5-HT<sub>5A</sub> receptors, because their transduction mechanism is negatively coupled to adenylyl cyclase and their activation opens and closes K<sup>+</sup> and Ca<sup>2+</sup> channels, respectively, hyperpolarizing neurons [<xref rid="B17-pharmaceutics-17-00330" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-17-00330" ref-type="bibr">18</xref>], which, in turn, are predominantly antinociceptive in pain animal models [<xref rid="B17-pharmaceutics-17-00330" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-17-00330" ref-type="bibr">18</xref>,<xref rid="B30-pharmaceutics-17-00330" ref-type="bibr">30</xref>,<xref rid="B49-pharmaceutics-17-00330" ref-type="bibr">49</xref>].</p><p>The data show that WAY100635 (5-HT<sub>1A</sub> receptor antagonist) decreased the sesamin-induced antinociceptive effect in the formalin test. In marked contrast, SB224289 (5-HT<sub>1B</sub> receptor antagonist), BRL15572 (5-HT<sub>1D</sub> receptor antagonist), and SB699551 (5-HT<sub>5A</sub> receptor antagonist) had no effect on antinociception induced by sesamin. The results strongly suggest that the antinociceptive effect of sesamin is mediated thought the activation of 5-HT<sub>1A</sub> receptors, but not 5-HT<sub>1B</sub>, 5-HT<sub>1D</sub>, or 5-HT<sub>5A</sub> receptors. Nonetheless, the participation of D4 receptors cannot be completely discarded because WAY100635 also binds to these receptors [<xref rid="B50-pharmaceutics-17-00330" ref-type="bibr">50</xref>]. In line with our results, it is well known that the main source of serotonin in the central nervous system is localized in the nucleus raphe magnus, which sends descending projections to the spinal cord, where the 5-HT<sub>1A</sub> receptor seems to be the predominant receptor for exerting the antinociceptive effect of serotonin [<xref rid="B51-pharmaceutics-17-00330" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceutics-17-00330" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceutics-17-00330" ref-type="bibr">53</xref>]. In addition, the selective activation of 5-HT<sub>1A</sub> receptors at the peripheral level leads to antinociception in the formalin test [<xref rid="B30-pharmaceutics-17-00330" ref-type="bibr">30</xref>]. Because the expression of 5-HT<sub>1A</sub> receptors has been observed on dorsal root ganglia [<xref rid="B54-pharmaceutics-17-00330" ref-type="bibr">54</xref>] as well as in the spinal cord and brain structures as mesencephalic raphe nuclei and several amygdaloidal and brainstem nuclei [<xref rid="B55-pharmaceutics-17-00330" ref-type="bibr">55</xref>], we speculate that the antinociceptive effect of sesamin may involve the peripheral and central activation of 5-HT<sub>1A</sub> receptors.</p></sec><sec sec-type="conclusions" id="sec5-pharmaceutics-17-00330"><title>5. Conclusions</title><p>In summary, our results confirm the antinociceptive effect of sesamin in inflammatory pain models in rats and evaluate, for the first time, its antiallodynic effect in a neuropathic pain test. The evidence suggests that sesamin is one of the main substances responsible for conferring anti-inflammatory and antinociceptive activities to the sesame plant, and this effect seems to be carried out through the activation of 5-HT<sub>1A</sub> receptors. In addition, this study validates the traditional use of sesame oil in the treatment of inflammatory pain disorders such as dysmenorrhea, abdominal pain, and migraine. Finally, sesamin may be useful alone or as an adjuvant in the treatment of painful disorders in human beings.</p></sec></body><back><ack><title>Acknowledgments</title><p>Roberto Camacho-Cruz is a CONAHCYT fellow (CVU number: 849680), and this work is part of his PhD dissertation.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, J.A.-V., A.N., and H.I.R.-G.; methodology, R.C.-C., D.F.A.-H., J.C.H.-C., and H.I.R.-G.; validation, M.E.S.-M., F.J.F.-M., J.G.R.-G., A.N., and H.I.R.-G.; formal analysis, R.C.-C., D.F.A.-H., J.C.H.-C., and H.I.R.-G.; investigation, R.C.-C., D.F.A.-H., J.C.H.-C., and J.G.R.-G.; resources, J.C.H.-C., J.A.-V., M.E.S.-M., F.J.F.-M., A.N., J.G.R.-G., and H.I.R.-G.; data curation, R.C.-C., D.F.A.-H., J.C.H.-C., and H.I.R.-G.; writing&#8212;original draft preparation, R.C.-C., J.A.-V., M.E.S.-M., A.N., J.G.R.-G., and H.I.R.-G.; writing&#8212;review and editing, J.C.H.-C., J.A.-V., M.E.S.-M., J.G.R.-G., F.J.F.-M., and H.I.R.-G.; visualization, R.C.-C., D.F.A.-H., J.C.H.-C., and H.I.R.-G.; supervision, J.C.H.-C., J.A.-V., M.E.S.-M., and H.I.R.-G. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Behavioral experiments were carried out according to the Guidelines on Ethical Standards for the Investigation of Experimental Pain in Animals [<xref rid="B56-pharmaceutics-17-00330" ref-type="bibr">56</xref>], the Official Mexican Norm (Technical Specification on the Production, Care and Use of Laboratory Animals, NOM-062-ZOO-1999), the AVMA Guidelines for the Euthanasia of Animals: 2020 Edition, and the ARRIVE guidelines 2.0 [<xref rid="B57-pharmaceutics-17-00330" ref-type="bibr">57</xref>]. In addition, the protocol was approved on 14 September 2022 by the Committee for the Care and Use of Laboratory Animals from INER (INER/CI/285/2022) in Mexico City, Mexico, with the code B19-22.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in this article; further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00330"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Elleuch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bedigian</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zitoun</surname><given-names>A.</given-names></name></person-group><article-title>Sesame (<italic toggle="yes">Sesamum indicum</italic> L.) Seeds in Food, Nutrition, and Health</article-title><source>Nuts and Seeds in Health and Disease Prevention</source><edition>1st ed.</edition><person-group person-group-type="editor"><name name-style="western"><surname>Preedy</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Ross Watson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>V.B.</given-names></name></person-group><publisher-name>Academic Press</publisher-name><publisher-loc>San Diego, CA, USA</publisher-loc><year>2011</year><fpage>1029</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1016/b978-0-12-375688-6.10122-7</pub-id></element-citation></ref><ref id="B2-pharmaceutics-17-00330"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Q.</given-names></name></person-group><article-title>Sesame (<italic toggle="yes">Sesamum indicum</italic> L.): A Comprehensive Review of Nutritional Value, Phytochemical Composition, Health Benefits, Development of Food, and Industrial Applications</article-title><source>Nutrients</source><year>2022</year><volume>14</volume><elocation-id>4079</elocation-id><pub-id pub-id-type="doi">10.3390/nu14194079</pub-id><pub-id pub-id-type="pmid">36235731</pub-id><pub-id pub-id-type="pmcid">PMC9573514</pub-id></element-citation></ref><ref id="B3-pharmaceutics-17-00330"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Afroz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zihad</surname><given-names>S.M.N.K.</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Rouf</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>I.N.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shilpi</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>A systematic review on antioxidant and antiinflammatory activity of Sesame (<italic toggle="yes">Sesamum indicum</italic> L.) oil and further confirmation of antiinflammatory activity by chemical profiling and molecular docking</article-title><source>Phytother. Res.</source><year>2019</year><volume>33</volume><fpage>2585</fpage><lpage>2608</lpage><pub-id pub-id-type="doi">10.1002/ptr.6428</pub-id><pub-id pub-id-type="pmid">31373097</pub-id></element-citation></ref><ref id="B4-pharmaceutics-17-00330"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mili</surname><given-names>A.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nandakumar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lobo</surname><given-names>R.</given-names></name></person-group><article-title>A comprehensive review on <italic toggle="yes">Sesamum indicum</italic> L.: Botanical, ethnopharmacological, phytochemical, and pharmacological aspects</article-title><source>J. Ethnopharmacol.</source><year>2021</year><volume>281</volume><fpage>114503</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2021.114503</pub-id><pub-id pub-id-type="pmid">34364969</pub-id></element-citation></ref><ref id="B5-pharmaceutics-17-00330"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majdalawieh</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Massri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nasrallah</surname><given-names>G.K.</given-names></name></person-group><article-title>A comprehensive review on the anti-cancer properties and mechanisms of action of sesamin, a lignan in sesame seeds (<italic toggle="yes">Sesamum indicum</italic>)</article-title><source>Eur. J. Pharmacol.</source><year>2017</year><volume>815</volume><fpage>512</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2017.10.020</pub-id><pub-id pub-id-type="pmid">29032105</pub-id></element-citation></ref><ref id="B6-pharmaceutics-17-00330"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Rejano</surname><given-names>C.J.F.</given-names></name><name name-style="western"><surname>Tayo</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>P.W.</given-names></name></person-group><article-title>Sesamin: A Promising Therapeutic Agent for Ameliorating Symptoms of Diabetes</article-title><source>Molecules</source><year>2023</year><volume>28</volume><elocation-id>7255</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28217255</pub-id><pub-id pub-id-type="pmid">37959677</pub-id><pub-id pub-id-type="pmcid">PMC10649669</pub-id></element-citation></ref><ref id="B7-pharmaceutics-17-00330"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>L.</given-names></name></person-group><article-title>A Comprehensive Review on Distribution, Pharmacological Properties, and Mechanisms of Action of Sesamin</article-title><source>J. Chem.</source><year>2022</year><volume>1</volume><fpage>236525</fpage><pub-id pub-id-type="doi">10.1155/2022/4236525</pub-id></element-citation></ref><ref id="B8-pharmaceutics-17-00330"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>An</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name></person-group><article-title>The Effects of Sesamin Supplementation on Obesity, Blood Pressure, and Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials</article-title><source>Front. Endocrinol.</source><year>2022</year><volume>13</volume><elocation-id>842152</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2022.842152</pub-id><pub-id pub-id-type="pmid">35311241</pub-id><pub-id pub-id-type="pmcid">PMC8931661</pub-id></element-citation></ref><ref id="B9-pharmaceutics-17-00330"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dalibalta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Majdalawieh</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Manjikian</surname><given-names>H.</given-names></name></person-group><article-title>Health benefits of sesamin on cardiovascular disease and its associated risk factors</article-title><source>Saudi Pharm. J.</source><year>2020</year><volume>28</volume><fpage>1276</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1016/j.jsps.2020.08.018</pub-id><pub-id pub-id-type="pmid">33132721</pub-id><pub-id pub-id-type="pmcid">PMC7584802</pub-id></element-citation></ref><ref id="B10-pharmaceutics-17-00330"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majdalawieh</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Yousef</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Abu-Yousef</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Nasrallah</surname><given-names>G.K.</given-names></name></person-group><article-title>Immunomodulatory and anti-inflammatory effects of sesamin: Mechanisms of action and future directions</article-title><source>Crit. Rev. Food Sci. Nutr.</source><year>2022</year><volume>62</volume><fpage>5081</fpage><lpage>5112</lpage><pub-id pub-id-type="doi">10.1080/10408398.2021.1881438</pub-id><pub-id pub-id-type="pmid">33544009</pub-id></element-citation></ref><ref id="B11-pharmaceutics-17-00330"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lima</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Perazzo</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Tavares Carvalho</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Bastos</surname><given-names>J.K.</given-names></name></person-group><article-title>Anti-inflammatory and analgesic activities of the ethanolic extracts from <italic toggle="yes">Zanthoxylum riedelianum</italic> (Rutaceae) leaves and stem bark</article-title><source>J. Pharm. Pharmacol.</source><year>2007</year><volume>59</volume><fpage>1151</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1211/jpp.59.8.0014</pub-id><pub-id pub-id-type="pmid">17725859</pub-id></element-citation></ref><ref id="B12-pharmaceutics-17-00330"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.L.</given-names></name></person-group><article-title>Antinociceptive and anti-inflammatory activities of ethyl acetate fraction from <italic toggle="yes">Zanthoxylum armatum</italic> in mice</article-title><source>Fitoterapia</source><year>2011</year><volume>82</volume><fpage>347</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2010.11.004</pub-id><pub-id pub-id-type="pmid">21059381</pub-id></element-citation></ref><ref id="B13-pharmaceutics-17-00330"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monteiro</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Chibli</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Vilela</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Rodarte</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>do Amaral</surname><given-names>M.d.P.</given-names></name><name name-style="western"><surname>Silv&#233;rio</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Ara&#250;jo</surname><given-names>A.L.</given-names></name><etal/></person-group><article-title>Antinociceptive and anti-inflammatory activities of the sesame oil and sesamin</article-title><source>Nutrients</source><year>2014</year><volume>6</volume><fpage>1931</fpage><lpage>1944</lpage><pub-id pub-id-type="doi">10.3390/nu6051931</pub-id><pub-id pub-id-type="pmid">24824289</pub-id><pub-id pub-id-type="pmcid">PMC4042560</pub-id></element-citation></ref><ref id="B14-pharmaceutics-17-00330"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.B.</given-names></name></person-group><article-title>Anxiolytic effects of sesamin in mice with chronic inflammatory pain</article-title><source>Nutr. Neurosci.</source><year>2016</year><volume>19</volume><fpage>231</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1179/1476830515Y.0000000015</pub-id><pub-id pub-id-type="pmid">25822813</pub-id></element-citation></ref><ref id="B15-pharmaceutics-17-00330"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.K.</given-names></name></person-group><article-title>Effects of (-)-Sesamin on Chronic Stress-Induced Anxiety Disorders in Mice</article-title><source>Neurochem. Res.</source><year>2017</year><volume>42</volume><fpage>1123</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1007/s11064-016-2146-z</pub-id><pub-id pub-id-type="pmid">27995494</pub-id></element-citation></ref><ref id="B16-pharmaceutics-17-00330"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>(+)-Sesamin attenuates chronic unpredictable mild stress-induced depressive-like behaviors and memory deficits via suppression of neuroinflammation</article-title><source>J. Nutr. Biochem.</source><year>2019</year><volume>64</volume><fpage>61</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2018.10.006</pub-id><pub-id pub-id-type="pmid">30445417</pub-id></element-citation></ref><ref id="B17-pharmaceutics-17-00330"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Rocha-Gonz&#225;lez</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Casta&#241;eda-Corral</surname><given-names>G.</given-names></name><name name-style="western"><surname>Arg&#252;elles</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Granados-Soto</surname><given-names>V.</given-names></name></person-group><article-title>Role of serotonin receptors in inflammatory pain</article-title><source>Acute Pain. Causes, Effects and Treatment</source><edition>1st ed.</edition><person-group person-group-type="editor"><name name-style="western"><surname>D&#8217;Alonso</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grasso</surname><given-names>K.L.</given-names></name></person-group><publisher-name>Nova Biomedical Books</publisher-name><publisher-loc>Hauppauge, NY, USA</publisher-loc><year>2009</year><comment>Chapter 1</comment><fpage>1</fpage><lpage>42</lpage></element-citation></ref><ref id="B18-pharmaceutics-17-00330"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heijmans</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mons</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>E.A.</given-names></name></person-group><article-title>A systematic review on descending serotonergic projections and modulation of spinal nociception in chronic neuropathic pain and after spinal cord stimulation</article-title><source>Mol. Pain</source><year>2021</year><volume>17</volume><fpage>17448069211043965</fpage><pub-id pub-id-type="doi">10.1177/17448069211043965</pub-id><pub-id pub-id-type="pmid">34662215</pub-id><pub-id pub-id-type="pmcid">PMC8527581</pub-id></element-citation></ref><ref id="B19-pharmaceutics-17-00330"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrag&#225;n-Iglesias</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mendoza-Garc&#233;s</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pineda-Farias</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Solano-Olivares</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Silverio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Flores-Murrieta</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Granados-Soto</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rocha-Gonz&#225;lez</surname><given-names>H.I.</given-names></name></person-group><article-title>Participation of peripheral P2Y1, P2Y6 and P2Y11 receptors in formalin-induced inflammatory pain in rats</article-title><source>Pharmacol. Biochem. Behav.</source><year>2015</year><volume>128</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2014.11.001</pub-id><pub-id pub-id-type="pmid">25449358</pub-id></element-citation></ref><ref id="B20-pharmaceutics-17-00330"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caram-Salas</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Reyes-Garc&#237;a</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bartoszyk</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Araiza-Salda&#241;a</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Ambriz-Tututi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rocha-Gonz&#225;lez</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Arreola-Espino</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Granados-Soto</surname><given-names>V.</given-names></name></person-group><article-title>Subcutaneous, intrathecal and periaqueductal grey administration of asimadoline and ICI-204448 reduces tactile allodynia in the rat</article-title><source>Eur. J. Pharmacol.</source><year>2007</year><volume>573</volume><fpage>75</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2007.06.034</pub-id><pub-id pub-id-type="pmid">17643411</pub-id></element-citation></ref><ref id="B21-pharmaceutics-17-00330"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoyer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Fozard</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Hartig</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Mylecharane</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Humphrey</surname><given-names>P.P.</given-names></name></person-group><article-title>International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)</article-title><source>Pharmacol. Rev.</source><year>1994</year><volume>46</volume><fpage>157</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/S0031-6997(25)06783-3</pub-id><pub-id pub-id-type="pmid">7938165</pub-id></element-citation></ref><ref id="B22-pharmaceutics-17-00330"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfeiffer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leopold</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brunner</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>B.</given-names></name></person-group><article-title>Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): Requirement for bioactivation to the free acid, NG-nitro-L-arginine</article-title><source>Br. J. Pharmacol.</source><year>1996</year><volume>118</volume><fpage>1433</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.1996.tb15557.x</pub-id><pub-id pub-id-type="pmid">8832069</pub-id><pub-id pub-id-type="pmcid">PMC1909689</pub-id></element-citation></ref><ref id="B23-pharmaceutics-17-00330"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trescot</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Datta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>H.</given-names></name></person-group><article-title>Opioid Pahrmacology</article-title><source>Pain Physician</source><year>2008</year><volume>11</volume><fpage>S133</fpage><lpage>S153</lpage><pub-id pub-id-type="doi">10.36076/ppj.2008/11/S133</pub-id><pub-id pub-id-type="pmid">18443637</pub-id></element-citation></ref><ref id="B24-pharmaceutics-17-00330"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forster</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Cliffe</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Bill</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Dover</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>D.</given-names></name><name name-style="western"><surname>Reilly</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>A.</given-names></name></person-group><article-title>A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635</article-title><source>Eur. J. Pharmacol.</source><year>1995</year><volume>281</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(95)00234-C</pub-id><pub-id pub-id-type="pmid">8566121</pub-id></element-citation></ref><ref id="B25-pharmaceutics-17-00330"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selkirk</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burton</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gaster</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Collin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Middlemiss</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Price</surname><given-names>G.W.</given-names></name></person-group><article-title>SB-224289&#8212;A novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity</article-title><source>Br. J. Pharmacol.</source><year>1998</year><volume>125</volume><fpage>202</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0702059</pub-id><pub-id pub-id-type="pmid">9776361</pub-id><pub-id pub-id-type="pmcid">PMC1565605</pub-id></element-citation></ref><ref id="B26-pharmaceutics-17-00330"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Price</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Burton</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Collin</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Duckworth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gaster</surname><given-names>L.</given-names></name><name name-style="western"><surname>G&#246;thert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>C.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Middlemiss</surname><given-names>D.N.</given-names></name></person-group><article-title>SB-216641 and BRL-15572&#8212;Compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors</article-title><source>Naunyn Schmiedebergs Arch. Pharmacol.</source><year>1997</year><volume>356</volume><fpage>312</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1007/PL00005056</pub-id><pub-id pub-id-type="pmid">9303567</pub-id></element-citation></ref><ref id="B27-pharmaceutics-17-00330"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corbett</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Heightman</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Bromidge</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Coggon</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Longley</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Roa</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.R.</given-names></name></person-group><article-title>Discovery of a potent and selective 5-ht5A receptor antagonist by high-throughput chemistry</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2005</year><volume>15</volume><fpage>4014</fpage><lpage>4018</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2005.06.024</pub-id><pub-id pub-id-type="pmid">16002289</pub-id></element-citation></ref><ref id="B28-pharmaceutics-17-00330"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rocha-Gonz&#225;lez</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Ram&#237;rez-Aguilar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Granados-Soto</surname><given-names>V.</given-names></name><name name-style="western"><surname>Reyes-Garc&#237;a</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Torres-L&#243;pez</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Huerta-Cruz</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Navarrete</surname><given-names>A.</given-names></name></person-group><article-title>Antineuropathic effect of 7-hydroxy-3,4-dihydrocadalin in streptozotocin-induced diabetic rodents</article-title><source>BMC Complement. Altern. Med.</source><year>2014</year><volume>14</volume><elocation-id>129</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6882-14-129</pub-id><pub-id pub-id-type="pmid">24708659</pub-id><pub-id pub-id-type="pmcid">PMC3984493</pub-id></element-citation></ref><ref id="B29-pharmaceutics-17-00330"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qui&#241;onez-Bastidas</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Pineda-Farias</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Flores-Murrieta</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Silverio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reyes-Garc&#237;a</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>God&#237;nez-Chaparro</surname><given-names>B.</given-names></name><name name-style="western"><surname>Granados-Soto</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rocha-Gonz&#225;lez</surname><given-names>H.I.</given-names></name></person-group><article-title>Antinociceptive effect of (-)-epicatechin in inflammatory and neuropathic pain in rats</article-title><source>Behav. Pharmacol.</source><year>2018</year><volume>29</volume><fpage>270</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1097/FBP.0000000000000320</pub-id><pub-id pub-id-type="pmid">28590304</pub-id></element-citation></ref><ref id="B30-pharmaceutics-17-00330"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granados-Soto</surname><given-names>V.</given-names></name><name name-style="western"><surname>Arg&#252;elles</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Rocha-Gonz&#225;lez</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>God&#237;nez-Chaparro</surname><given-names>B.</given-names></name><name name-style="western"><surname>Flores-Murrieta</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Villal&#243;n</surname><given-names>C.M.</given-names></name></person-group><article-title>The role of peripheral 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F serotonergic receptors in the reduction of nociception in rats</article-title><source>Neuroscience</source><year>2010</year><volume>165</volume><fpage>561</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2009.10.020</pub-id><pub-id pub-id-type="pmid">19837141</pub-id></element-citation></ref><ref id="B31-pharmaceutics-17-00330"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phitak</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pothacharoen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Settakorn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Poompimol</surname><given-names>W.</given-names></name><name name-style="western"><surname>Caterson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kongtawelert</surname><given-names>P.</given-names></name></person-group><article-title>Chondroprotective and anti-inflammatory effects of sesamin</article-title><source>Phytochemistry</source><year>2012</year><volume>80</volume><fpage>77</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.phytochem.2012.05.016</pub-id><pub-id pub-id-type="pmid">22704650</pub-id></element-citation></ref><ref id="B32-pharmaceutics-17-00330"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liigand</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arndt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Greiner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wishart</surname><given-names>D.S.</given-names></name></person-group><article-title>CFM-ID 4.0: More Accurate ESI-MS/MS Spectral Prediction and Compound Identification</article-title><source>Anal. Chem.</source><year>2021</year><volume>93</volume><fpage>11692</fpage><lpage>11700</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.1c01465</pub-id><pub-id pub-id-type="pmid">34403256</pub-id><pub-id pub-id-type="pmcid">PMC9064193</pub-id></element-citation></ref><ref id="B33-pharmaceutics-17-00330"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubuisson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dennis</surname><given-names>S.G.</given-names></name></person-group><article-title>The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats</article-title><source>Pain</source><year>1977</year><volume>4</volume><fpage>161</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(77)90130-0</pub-id><pub-id pub-id-type="pmid">564014</pub-id></element-citation></ref><ref id="B34-pharmaceutics-17-00330"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wheeler-Aceto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cowan</surname><given-names>A.</given-names></name></person-group><article-title>Standardization of the rat paw formalin test for the evaluation of analgesics</article-title><source>Psychopharmacology</source><year>1991</year><volume>104</volume><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1007/BF02244551</pub-id><pub-id pub-id-type="pmid">1882002</pub-id></element-citation></ref><ref id="B35-pharmaceutics-17-00330"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dirig</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Salami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rathbun</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Ozaki</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Yaksh</surname><given-names>T.L.</given-names></name></person-group><article-title>Characterization of variables defining hindpaw withdrawal latency evoked by radiant thermal stimuli</article-title><source>J. Neurosci. Methods</source><year>1997</year><volume>76</volume><fpage>183</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/S0165-0270(97)00097-6</pub-id><pub-id pub-id-type="pmid">9350970</pub-id></element-citation></ref><ref id="B36-pharmaceutics-17-00330"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winder</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Wax</surname><given-names>J.</given-names></name><name name-style="western"><surname>Been</surname><given-names>M.A.</given-names></name></person-group><article-title>Rapid foot volume measurements on unanesthetized rats, and the question of a phenylbutazone effect on anaphylactoid edema</article-title><source>Arch. Int. Pharmacodyn. Ther.</source><year>1957</year><volume>112</volume><fpage>174</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">13498848</pub-id></element-citation></ref><ref id="B37-pharmaceutics-17-00330"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaplan</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Bach</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Pogrel</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Yaksh</surname><given-names>T.L.</given-names></name></person-group><article-title>Quantitative assessment of tactile allodynia in the rat paw</article-title><source>J. Neurosci. Methods</source><year>1994</year><volume>53</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/0165-0270(94)90144-9</pub-id><pub-id pub-id-type="pmid">7990513</pub-id></element-citation></ref><ref id="B38-pharmaceutics-17-00330"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dixon</surname><given-names>W.J.</given-names></name></person-group><article-title>Efficient analysis of experimental observations</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><year>1980</year><volume>20</volume><fpage>441</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1146/annurev.pa.20.040180.002301</pub-id><pub-id pub-id-type="pmid">7387124</pub-id></element-citation></ref><ref id="B39-pharmaceutics-17-00330"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thrall</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Vucelick</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Gies</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Zangar</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Weitz</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Poet</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Springer</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Grant</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Benson</surname><given-names>J.M.</given-names></name></person-group><article-title>Comparative metabolism of carbon tetrachloride in rats, mice, and hamsters using gas uptake and PBPK modeling</article-title><source>J. Toxicol. Environ. Health A</source><year>2000</year><volume>60</volume><fpage>531</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1080/00984100050082085</pub-id><pub-id pub-id-type="pmid">10983521</pub-id></element-citation></ref><ref id="B40-pharmaceutics-17-00330"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tulip</surname><given-names>K.</given-names></name><name name-style="western"><surname>Timbrell</surname><given-names>J.A.</given-names></name></person-group><article-title>Comparative hepatotoxicity and metabolism of N-methylformamide in rats and mice</article-title><source>Arch. Toxicol.</source><year>1988</year><volume>62</volume><fpage>167</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1007/BF00570135</pub-id><pub-id pub-id-type="pmid">3196150</pub-id></element-citation></ref><ref id="B41-pharmaceutics-17-00330"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Helli</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shahi</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Mowla</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jalali</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Haghighian</surname><given-names>H.K.</given-names></name></person-group><article-title>A randomized, triple-blind, placebo-controlled clinical trial, evaluating the sesamin supplement effects on proteolytic enzymes, inflammatory markers, and clinical indices in women with rheumatoid arthritis</article-title><source>Phytother. Res.</source><year>2019</year><volume>33</volume><fpage>2421</fpage><lpage>2428</lpage><pub-id pub-id-type="doi">10.1002/ptr.6433</pub-id><pub-id pub-id-type="pmid">31309643</pub-id></element-citation></ref><ref id="B42-pharmaceutics-17-00330"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGettigan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>D.</given-names></name></person-group><article-title>Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: An examination of sales and essential medicines lists in low-, middle-, and high-income countries</article-title><source>PLoS Med.</source><year>2013</year><volume>10</volume><elocation-id>e1001388</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1001388</pub-id><pub-id pub-id-type="pmid">23424288</pub-id><pub-id pub-id-type="pmcid">PMC3570554</pub-id></element-citation></ref><ref id="B43-pharmaceutics-17-00330"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>H.</given-names></name></person-group><article-title>Promotive effects of sesamin on proliferation and adhesion of intestinal probiotics and its mechanism of action</article-title><source>Food Chem. Toxicol.</source><year>2021</year><volume>149</volume><fpage>112049</fpage><pub-id pub-id-type="doi">10.1016/j.fct.2021.112049</pub-id><pub-id pub-id-type="pmid">33561518</pub-id></element-citation></ref><ref id="B44-pharmaceutics-17-00330"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wirth</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lafforgue</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>T.</given-names></name></person-group><article-title>NSAID: Current limits to prescription</article-title><source>Jt. Bone Spine</source><year>2024</year><volume>91</volume><fpage>105685</fpage><pub-id pub-id-type="doi">10.1016/j.jbspin.2023.105685</pub-id><pub-id pub-id-type="pmid">38159794</pub-id></element-citation></ref><ref id="B45-pharmaceutics-17-00330"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name></person-group><article-title>Sesamin attenuates carrageenan-induced lung inflammation through upregulation of A20 and TAX1BP1 in rats</article-title><source>Int. Immunopharmacol.</source><year>2020</year><volume>88</volume><fpage>107009</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2020.107009</pub-id><pub-id pub-id-type="pmid">33182047</pub-id></element-citation></ref><ref id="B46-pharmaceutics-17-00330"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>V.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Singh Jaggi</surname><given-names>A.</given-names></name></person-group><article-title>Pregabalin in neuropathic pain: Evidences and possible mechanisms</article-title><source>Curr. Neuropharmacol.</source><year>2014</year><volume>12</volume><fpage>44</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.2174/1570159X1201140117162802</pub-id><pub-id pub-id-type="pmid">24533015</pub-id><pub-id pub-id-type="pmcid">PMC3915349</pub-id></element-citation></ref><ref id="B47-pharmaceutics-17-00330"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sandireddy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yerra</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Areti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Komirishetty</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name></person-group><article-title>Neuroinflammation and oxidative stress in diabetic neuropathy: Futuristic strategies based on these targets</article-title><source>Int. J. Endocrinol.</source><year>2014</year><volume>2014</volume><fpage>674987</fpage><pub-id pub-id-type="doi">10.1155/2014/674987</pub-id><pub-id pub-id-type="pmid">24883061</pub-id><pub-id pub-id-type="pmcid">PMC4021687</pub-id></element-citation></ref><ref id="B48-pharmaceutics-17-00330"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodr&#237;guez-Silverio</surname><given-names>J.</given-names></name><name name-style="western"><surname>S&#225;nchez-Mendoza</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Rocha-Gonz&#225;lez</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Reyes-Garc&#237;a</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Flores-Murrieta</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>L&#243;pez-Lorenzo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qui&#241;onez-Bastidas</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Arrieta</surname><given-names>J.</given-names></name></person-group><article-title>Evaluation of the Antinociceptive, Antiallodynic, Antihyperalgesic and Anti-Inflammatory Effect of Polyalthic Acid</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>2921</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26102921</pub-id><pub-id pub-id-type="pmid">34069033</pub-id><pub-id pub-id-type="pmcid">PMC8155873</pub-id></element-citation></ref><ref id="B49-pharmaceutics-17-00330"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mu&#241;oz-Islas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vidal-Cant&#250;</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Bravo-Hern&#225;ndez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cervantes-Dur&#225;n</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qui&#241;onez-Bastidas</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Pineda-Farias</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Barrag&#225;n-Iglesias</surname><given-names>P.</given-names></name><name name-style="western"><surname>Granados-Soto</surname><given-names>V.</given-names></name></person-group><article-title>Spinal 5-HT<sub>5</sub>A receptors mediate 5-HT-induced antinociception in several pain models in rats</article-title><source>Pharmacol. Biochem. Behav.</source><year>2014</year><volume>120</volume><fpage>25</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2014.02.001</pub-id><pub-id pub-id-type="pmid">24517902</pub-id></element-citation></ref><ref id="B50-pharmaceutics-17-00330"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chemel</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Armbruster</surname><given-names>B.</given-names></name><name name-style="western"><surname>Watts</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>D.E.</given-names></name></person-group><article-title>WAY-100635 is a potent dopamine D4 receptor agonist</article-title><source>Psychopharmacology</source><year>2006</year><volume>188</volume><fpage>244</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1007/s00213-006-0490-4</pub-id><pub-id pub-id-type="pmid">16915381</pub-id></element-citation></ref><ref id="B51-pharmaceutics-17-00330"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Millan</surname><given-names>M.J.</given-names></name></person-group><article-title>Descending control of pain</article-title><source>Prog. Neurobiol.</source><year>2002</year><volume>66</volume><fpage>355</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/s0301-0082(02)00009-6</pub-id><pub-id pub-id-type="pmid">12034378</pub-id></element-citation></ref><ref id="B52-pharmaceutics-17-00330"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Vaughan</surname><given-names>C.W.</given-names></name></person-group><article-title>Role of 5-HT(1) receptor subtypes in the modulation of pain and synaptic transmission in rat spinal superficial dorsal horn</article-title><source>Br. J. Pharmacol.</source><year>2012</year><volume>165</volume><fpage>1956</fpage><lpage>1965</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01685.x</pub-id><pub-id pub-id-type="pmid">21950560</pub-id><pub-id pub-id-type="pmcid">PMC3372843</pub-id></element-citation></ref><ref id="B53-pharmaceutics-17-00330"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bae</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.I.</given-names></name></person-group><article-title>Spinal 5-HT1A, not the 5-HT1B or 5-HT3 receptors, mediates descending serotonergic inhibition for late-phase mechanical allodynia of carrageenan-induced peripheral inflammation</article-title><source>Neurosci. Lett.</source><year>2015</year><volume>600</volume><fpage>91</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2015.05.058</pub-id><pub-id pub-id-type="pmid">26037417</pub-id></element-citation></ref><ref id="B54-pharmaceutics-17-00330"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.Q.</given-names></name></person-group><article-title>Changes of 5-HT receptor subtype mRNAs in rat dorsal root ganglion by bee venom-induced inflammatory pain</article-title><source>Neurosci. Lett.</source><year>2005</year><volume>375</volume><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2004.10.064</pub-id><pub-id pub-id-type="pmid">15664120</pub-id></element-citation></ref><ref id="B55-pharmaceutics-17-00330"><label>55.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Vilar&#243;</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Cort&#233;s</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mengod</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hoyer</surname><given-names>D.</given-names></name></person-group><article-title>Distribution of 5-HT receptors in the central nervous system: An update</article-title><source>Handbook of Behavioral Neuroscience</source><edition>2nd ed.</edition><person-group person-group-type="editor"><name name-style="western"><surname>M&#252;ller</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>K.A.</given-names></name></person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2020</year><volume>Volume 31</volume><fpage>121</fpage><lpage>146</lpage></element-citation></ref><ref id="B56-pharmaceutics-17-00330"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>M.</given-names></name></person-group><article-title>Ethical guidelines for investigations of experimental pain in conscious animals</article-title><source>Pain</source><year>1983</year><volume>16</volume><fpage>109</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(83)90201-4</pub-id><pub-id pub-id-type="pmid">6877845</pub-id></element-citation></ref><ref id="B57-pharmaceutics-17-00330"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Percie du Sert</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hurst</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ahluwalia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Avey</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Browne</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cuthill</surname><given-names>I.C.</given-names></name><name name-style="western"><surname>Dirnagl</surname><given-names>U.</given-names></name><etal/></person-group><article-title>The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research</article-title><source>PLoS Biol.</source><year>2020</year><volume>18</volume><elocation-id>e3000410</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3000410</pub-id><pub-id pub-id-type="pmid">32663219</pub-id><pub-id pub-id-type="pmcid">PMC7360023</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00330-f001" orientation="portrait"><label>Figure 1</label><caption><p>(<bold>A</bold>) The time course of the antinociceptive effect observed after the oral administration of sesamin (3.2 mg/kg) or diclofenac (32 mg/kg) in rats subjected to a subcutaneous injection of 1% formalin. (<bold>B</bold>,<bold>C</bold>) The dose&#8211;response curves of sesamin (0.32&#8211;10 mg/kg) and diclofenac (1&#8211;32 mg/kg) obtained during phase 1 and phase 2 of the formalin test in rats. The data are expressed as the mean &#177; S.E.M. from six rats per experimental group. (a) Significantly different from vehicle group (Veh) according to analysis of variance (ANOVA), followed by Tukey&#8217;s test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-00330-g001.jpg"/></fig><fig position="float" id="pharmaceutics-17-00330-f002" orientation="portrait"><label>Figure 2</label><caption><p>(<bold>A</bold>,<bold>C</bold>) The time course of the antihyperalgesic and anti-inflammatory effects observed after the oral administration of sesamin (32 mg/kg) or diclofenac (32 mg/kg) in rats subjected to an intraplantar injection of 1% carrageenan. (<bold>B</bold>,<bold>D</bold>) Dose&#8211;response curves obtained from the antihyperalgesic and anti-inflammatory effects induced by increasing oral doses of sesamin (3.2&#8211;32 mg/kg) or diclofenac (3.2&#8211;32 mg/kg) in rats subjected to an intraplanar injection of 1% carrageenan. Data are expressed as the mean &#177; S.E.M. from 6&#8211;8 rats per experimental group. (a) Significantly different from vehicle group (Veh) according to analysis of variance (ANOVA), followed by Tukey&#8217;s test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-00330-g002.jpg"/></fig><fig position="float" id="pharmaceutics-17-00330-f003" orientation="portrait"><label>Figure 3</label><caption><p>(<bold>A</bold>) The time course of the antiallodynic effect observed after the oral administration of sesamin (100 mg/kg) or pregabalin (30 mg/kg) in rats subjected to the ligation of spinal nerves L5/L6. (<bold>B</bold>) Dose&#8211;response curves of sesamin (3.2&#8211;100 mg/kg) or pregabalin (0.32&#8211;32 mg/kg) obtained in the L5-6-spinal-nerve-ligation-induced neuropathy model in rats. Data are expressed as the mean &#177; S.E.M. from six rats per experimental group. (a) Significantly different from vehicle group (Veh) via analysis of variance (ANOVA), followed by Tukey&#8217;s test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-00330-g003.jpg"/></fig><fig position="float" id="pharmaceutics-17-00330-f004" orientation="portrait"><label>Figure 4</label><caption><p>(<bold>A</bold>,<bold>C</bold>,<bold>E</bold>) The time courses of the antinociceptive effect observed after the oral administration of sesamin alone, sesamin and naltrexone, sesamin and L-NAME, or sesamin and methiothepin in the formalin test. (<bold>B</bold>,<bold>D</bold>,<bold>F</bold>) The effect of the intraperitoneal administration of naltrexone (1 mg/kg, &#8722;30 min), L-NAME (0.1 mg/kg, &#8722;30 min), or methiothepin (1 mg/kg, &#8722;30 min) on sesamin (3.2 mg/kg, &#8722;60 min)-induced antinociception in phase 2 of the formalin test. Bars are the mean &#177; S.E.M. from six rats per experimental group. (a) Significantly different from vehicle group (Veh); (b) significantly different from sesamin group via analysis of variance (ANOVA), followed by Tukey&#8217;s test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-00330-g004.jpg"/></fig><fig position="float" id="pharmaceutics-17-00330-f005" orientation="portrait"><label>Figure 5</label><caption><p>(<bold>A</bold>,<bold>C</bold>,<bold>E</bold>,<bold>G</bold>) The time courses of the antinociceptive effect observed after the oral administration of sesamin alone, sesamin and WAY100635, sesamin and SB224289, sesamin and BRL15572, or sesamin and SB699551 in the formalin test. (<bold>B</bold>,<bold>D</bold>,<bold>F</bold>,<bold>H</bold>) The effect of the intraperitoneal administration of WAY100635 (30 &#956;g/kg, -30 min), SB224289 (3 &#956;g/kg, -30 min), BRL15572 (30 &#956;g/kg, -30 min), or SB699551 (30 &#956;g/kg, -30 min) on sesamin (3.2 mg/kg, -60 min)-induced antinociception in phase 2 of the formalin test. Bars are the mean &#177; S.E.M. from six rats per experimental group. (a) Significantly different from the vehicle group (Veh); (b) significantly different from the sesamin group via analysis of variance (ANOVA), followed by Tukey&#8217;s test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-00330-g005.jpg"/></fig></floats-group></article></pmc-articleset>